Clene biopharma gets $1 million Maryland grant for Elkton location

285
Advertisement

Clene Inc., a clinical-stage biopharmaceutical company received  a $1 million grant award from the Maryland Department of Housing and Community Development (DHCD) to further support the redevelopment of the Clene manufacturing facility in Elkton, MD.

The company is based in Salt Lake City and has a site in North East, MD.

The former W.L. Gore  site near the Delaware state line is being redeveloped to increase Clene’s manufacturing capacity and support anticipated product commercialization for amyotrophic lateral sclerosis (ALS) with Clene’s, CNM-Au8.

“Clene is committed to supporting the infrastructure growth of the Maryland community, and we are grateful for this recognition by the State of Maryland and the assistance of the Town of Elkton,” said Mark Mortenson, founder & chief scientific officer of Clene Nanomedicine. “Maryland’s community of innovators and state-of-the-art facilities will enable the accelerated development of Clene’s neuroprotective therapeutic. We look forward to expanding our partnership with the state and the Town of Elkton.”

Clene’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system.

Advertisement

CNM-Au8 is currently being evaluated in a Phase 3 registration trial in amyotrophic lateral sclerosis (Lou Gehrig’s Disease) and a Phase 2 trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS).

The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com.

Advertisement
Advertisement